Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer

Journal of the National Cancer Institute

Volumn 104, Issue 24, 2012, Pages 1879-1887

  Groheux, David ^a,e   Hindié, Elif ^a,d,e   Delord, Marc ^e   Giacchetti, Sylvie ^b   Hamy, Anne Sophie ^b   De Bazelaire, Cédric ^c   De Roquancourt, Anne ^c   Vercellino, Laetitia ^a   Toubert, Marie Elisabeth ^a   Merlet, Pascal ^a   Espié, Marc ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b Department of Medical Oncology   (France)

^c Department of Radiology ^*  (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GERMANIUM DERIVATIVE; GERMANIUM OXYORTHOSILICATE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EXAMINATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; ECHOMAMMOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY;

EID: 84871842303     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs451     Document Type: Article

References (30)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
2. Groheux D, Hindié E, Rubello D, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36(10):1539-1542.
3. Hindié E, Groheux D, Brenot-Rossi I, Rubello D, Moretti JL, Espié M. The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med. 2011;52(3):405-414.
4. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109(3):417-426.
5. Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50(2):231-238.
6. Alberini J-L, Lerebours F, Wartski M, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115(21):5038-5047.
7. Groheux D, Moretti J-L, Baillet G, et al. Effect of 18F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):695-704.
8. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746-4751.
9. Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16(6):617-624.
10. Aukema TS, Straver ME, Peeters MJ, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer. 2010;46(18):3205-3210.
11. Groheux D, Giacchetti S, Espié M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med. 2011;52(10):1526-3154.
12. Koolen BB, Vrancken Peeters MJ, Aukema TS, et al. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012;131(1):117-126.
13. Bourguet P, Hitzel A, Houvenaeghel G et al. Synthesis bulletin of 2005 surveillance. Clinical practice recommendations: the use of PET-FDG in cancers of the breast, ovary and uterus. Bull Cancer. 2006;93(4):385-390.
14. Yap CS, Seltzer MA, Schiepers C, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med. 2001;42(9):1334-1337.
15. Schirrmeister H, Kühn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28(3):351-358.
16. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27(4):407-410.
17. Van der hoeven JJ, Krak NC, Hoekstra OS, et al. 18F-2-fluoro-2-deoxyd- glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22(7):1253-1259.
18. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36(10):1543-1550.
19. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237(2):627-634.
20. Groheux D, Giacchetti S, Moretti J-L, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-435.
21. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715-1724.
22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. Version 2, 2012. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed July 11, 2012.
23. Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010;28(19):3154-3159.
24. Park HJ, Shin KH, Cho KH, et al. Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy. Int J Radiat Oncol Biol Phys. 2011;81(5):689-695.
25. Walker GV, Niikura N, Yang W, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83(5):1381-1386.
26. Brito RA, Valero V, Buzdar AU, et al. Long-term results of combinedmodality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001;19(3):628-633.
27. Groheux D, Hindié E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53(2):249-254.
28. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423-428.
29. Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411-2418.
30. Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 trial-CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012; 30(26)3242-3249.